Utility of High Flow Nasal Cannula in CO Toxicity

NCT ID: NCT03342209

Last Updated: 2018-04-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 35 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-03-01
• Study Completion Date: 2018-02-06

Brief Summary

determination of the half-life of COHb in CO-poisoned patients with high flow nasal oxygen therapy in the ED.

Detailed Description

Carbon monoxide (CO) poisoning is common and potentially fatal environmental emergency which requires immediate attention. It is responsible for up to 40,000 emergency department (ED) visits and 5000 to 6000 deaths per year, making it one of the leading causes of poisoning death in the United States. The management options for CO poisoning are limited to high flow oxygen by face mask or hyperbaric oxygen treatment. While half-life of carboxyhemoglobin (COHb) in a patient treating with high flow oxygen via a nonbreathing face mask is 90 minutes, it becomes 30 minutes with hyperbaric oxygen treatment (HBO).

The hypothesis of this study is using high flow nasal oxygen therapy in the CO poisoning may be more effective and safer treatment method comparing to standard oxygen therapy in the ED. Also, it may be a safe promising alternative of hyperbaric oxygen therapy.

The aim of the study is to determine the half-life of COHb in CO-poisoned patients with high flow nasal oxygen therapy in the ED.

Conditions

Carbon Monoxide Poisoning; Environmental Exposure

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HFNC therapy

Fisher\&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy will be implemented to CO-poisoned patients. Oxygen flow rate will be started 60 L/min and be decreased as the patient has requested.

Group Type: EXPERIMENTAL

Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy

Intervention Type: DEVICE

A high flow nasal cannula will be implemented to the CO-poisoned patients. In the meantime, intravenous access and cardiac monitorization will have been establishing. When the high flow nasal cannula becomes ready, the first venous blood sample will be taken and the treatment will be started without any delay. The gas flow rate will be started at the rate of 30 liters per minute and will be increased to the max flow rate which patient can tolerate and FiO2 of 1.0. If the first COHb level is lesser than 10%, the patient will be excluded and will receive standard emergency care.

The blood sample will be drawn from existing IV access every 10 minutes until the COHb levels become %50 or lesser of the initial level.

Once the COHb level becomes 50% of initial measurement, following blood samples will be taken in every 30 minutes.

Interventions

Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy

A high flow nasal cannula will be implemented to the CO-poisoned patients. In the meantime, intravenous access and cardiac monitorization will have been establishing. When the high flow nasal cannula becomes ready, the first venous blood sample will be taken and the treatment will be started without any delay. The gas flow rate will be started at the rate of 30 liters per minute and will be increased to the max flow rate which patient can tolerate and FiO2 of 1.0. If the first COHb level is lesser than 10%, the patient will be excluded and will receive standard emergency care.

The blood sample will be drawn from existing IV access every 10 minutes until the COHb levels become %50 or lesser of the initial level.

Once the COHb level becomes 50% of initial measurement, following blood samples will be taken in every 30 minutes.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• The patients who are admitted to the emergency department with CO poisoning with a CoHB level of >10%.
• The patients who accept to participate in the study.

Exclusion Criteria

• The patients who are <18 years old.
• The patients who need mechanical ventilation
• The patients who are implemented oxygen more than 30 minutes before the ED admission
• The patients who will be transferred to the hyperbaric oxygen center before the CoHB levels are decreased to the half.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kocaeli University

OTHER

Sponsor Role: lead

Responsible Party

Ibrahim Ulas Ozturan

Principle Investigator, MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Elif Yaka, Assoc. Prof.

Role: STUDY_CHAIR

Kocaeli University

İbrahim U Özturan

Role: PRINCIPAL_INVESTIGATOR

Kocaeli University

Locations

Kocaeli University Medical Faculty

Kocaeli, Izmit, Turkey (Türkiye)

Countries

Turkey (Türkiye)

Other Identifiers

KIA 2016/286

Identifier Type: -

Identifier Source: org_study_id